CXCR4 and colorectal carcinoma: Once CXCR4‐dependence for T22‐GFP‐H6‐FdU in vitro activity was established, we investigated whether the nanoconjugate could achieve targeted drug delivery after its intravenous administration in the subcutaneous (SC) CXCR4+ SW1417 CRC model.